Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 09-2025 | 03-2025 | 09-2024 | 03-2024 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,343 | -6,067 | -2,757 | -6,739 | -2,914 |
| Depreciation Amortization | 217 | 343 | 158 | 103 | 18 |
| Accounts receivable | -1 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -338 | N/A | N/A | N/A | N/A |
| Other Working Capital | -460 | 626 | 568 | -1,120 | -586 |
| Other Operating Activity | 165 | 534 | 112 | 1,509 | 24 |
| Operating Cash Flow | $-2,760 | $-4,564 | $-1,919 | $-6,247 | $-3,458 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -142 | -604 | -248 | -952 | -493 |
| Other Investing Activity | 0 | 0 | 0 | -212 | -215 |
| Investing Cash Flow | $-142 | $-604 | $-248 | $-1,164 | $-708 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,071 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -52 | 5,807 | 5,863 | 1,648 | -79 |
| Financing Cash Flow | $2,018 | $5,807 | $5,863 | $1,648 | $-79 |
| Beginning Cash Position | 4,229 | 3,589 | 3,589 | 9,353 | 9,353 |
| End Cash Position | 3,346 | 4,229 | 7,286 | 3,589 | 5,108 |
| Net Cash Flow | $-884 | $640 | $3,697 | $-5,763 | $-4,245 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,760 | -4,564 | -1,919 | -6,247 | -3,458 |
| Capital Expenditure | -142 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -2,902 | -4,564 | -1,919 | -6,247 | -3,458 |